ATP5MF-PTCD1

Across TCGA pan-cancer cohorts, ATP5MF-PTCD1 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated ATP5MF-PTCD1 data layer compared with 2 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ATP5MF-PTCD1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP5MF-PTCD1 expression acts as an unfavorable survival marker, although some lineages such as BRCA and KIRP show a favorable association.

KIRC, KICH, and SCLC are the cancer types where ATP5MF-PTCD1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Tertile	IV	0.193	0.479	<.001	134	view →
KICH	DFS	Median	All	0.628	1.000	.001	75	view →
SCLC	OS	Tertile	All	0.438	0.815	<.001	59	view →
UVM	OS	Tertile	All	0.371	0.797	.001	57	view →
LGG	DFS	Median	All	0.320	0.466	<.001	38	view →
BRCA	OS	Tertile	II,III,IV	0.950	0.868	<.001	32	view →
COAD	DFS	Tertile	IV	0.394	0.732	.009	26	view →
THCA	DFS	Quartile	III,IV	0.780	0.913	.010	25	view →
KIRP	DFS	Quartile	All	1.000	0.508	.003	21	view →
PRAD	DFS	Median	All	0.664	0.876	<.001	18	view →
DLBC	DFS	Tertile	All	0.936	0.500	.015	13	view →
ACC	DFS	Tertile	All	0.234	0.589	.007	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

ATP5MF-PTCD1–KIRC (DFS)

Open the KIRC breakdown →